Research & Development
EPMC Pharma has been selected as an SME partner in the European FP7 initiative to develop new formulations of off-patent medicines for the at-term and pre-term new born.
Members of the EPMC Pharma team regularly meet with pharmacologists, paediatricians and health sector administrators as part of own development activities within this initiative. We are working to identify and source innovative treatments for neonatal children: one example being ‘Sucrose 24%’, an aqueous sterile oral solution used as a complement to medicines and other treatments.
